Segura-Castillo Jose Luis, Arias-Merino Elva Dolores, González-Ojeda Alejandro, Delgado-Hernández Gonzalo, Vázquez-Sánchez Sergio Jiram, Gómez-Sierra José Pablo, García Andrea, González-Muñoz Samantha Emily, Sánchez-Luna Ana Guadalupe, Morfín-Meza Kathia Dayana, Cervantes-Guevara Gabino, Cervantes-Pérez Enrique, Ramírez-Ochoa Sol, Fuentes-Orozco Clotilde
From the Department of Hand Surgery, General Hospital of Zone 89, Mexican Social Security Institute, Guadalajara, Mexico.
Department of Public Health, University of Guadalajara. Guadalajara, Jalisco, Mexico.
Plast Reconstr Surg Glob Open. 2025 Jun 19;13(6):e6883. doi: 10.1097/GOX.0000000000006883. eCollection 2025 Jun.
Diabetes, affecting 415 million adults globally, leads to collagen-related hand issues. Stenosing tenosynovitis, common in patients with diabetes, is often managed nonoperatively. Collagen-povidone, with safety demonstrated in rheumatoid arthritis, emerges as a potential intervention.
A randomized clinical trial conducted between January 2021 and January 2023 compared a povidone-collagen intervention with a placebo in adults aged 60 and older diagnosed with stenosing tenosynovitis. Participants were randomized into case (collagen-povidone) and control (physiological solution) groups. The study systematically assessed clinical outcomes such as the severity of stenosing tenosynovitis, diabetes, pain, functional capacity, and grip strength.
The trial included 25 older adults, with both groups showing no significant age difference. Predominant symptoms included pain, limitation of joint movement, pressure pain, and increased volume. Evolution time in stenosing tenosynovitis showed no significant difference. Both groups displayed stage II pain preintervention. Postintervention, the case group demonstrated a significant reduction in pain. The Kapandji test and hand grip strength significantly improved in the case group compared with controls. No complications were observed.
The clinical intervention yielded noteworthy improvements in pain and hand functionality. This study underscored the potential benefits of collagen-povidone in hand complications associated with diabetes, emphasizing the necessity for increased attention and research in this area, given the limited existing literature, which mainly consists of controlled studies.
糖尿病影响着全球4.15亿成年人,会导致与胶原蛋白相关的手部问题。狭窄性腱鞘炎在糖尿病患者中很常见,通常采用非手术治疗。胶原蛋白聚维酮在类风湿性关节炎中的安全性已得到证实,成为一种潜在的干预措施。
2021年1月至2023年1月进行的一项随机临床试验,将聚维酮 - 胶原蛋白干预措施与安慰剂对60岁及以上被诊断为狭窄性腱鞘炎的成年人进行比较。参与者被随机分为病例组(胶原蛋白聚维酮)和对照组(生理盐水)。该研究系统地评估了临床结果,如狭窄性腱鞘炎的严重程度、糖尿病情况、疼痛、功能能力和握力。
该试验纳入了25名老年人,两组在年龄上无显著差异。主要症状包括疼痛、关节活动受限、压痛和体积增大。狭窄性腱鞘炎的病程时间无显著差异。两组在干预前均表现为II期疼痛。干预后,病例组疼痛明显减轻。与对照组相比,病例组的卡潘迪试验和握力显著改善。未观察到并发症。
该临床干预在疼痛和手部功能方面取得了显著改善。鉴于现有文献有限且主要为对照研究,本研究强调了胶原蛋白聚维酮在糖尿病相关手部并发症中的潜在益处,凸显了该领域加强关注和研究的必要性。